Abstract

Dose optimisation of medicines for secondary prevention of MI provides evidence‐based benefits, but studies show that ACE inhibitors and beta‐blockers are prescribed at suboptimal doses on discharge and are not appropriately up‐titrated thereafter. Here we look at the reasons why and the possible solutions.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call